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Abstract
Background: During inflammation, immune cells accumulate in damaged areas and release pro-inflammatory
cytokines and neurotrophins. Brain-derived neurotrophic factor (BDNF) plays a neuromodulatory role in spinal cord
dorsal horn via the post-synaptic tyrosine protein kinase B (trkB) receptor to facilitate pain transmission. However,
the precise role of BDNF and trkB receptor in the primary sensory neurons of dorsal root ganglia (DRG) during
inflammation remains to be clarified. The aim of this study was to investigate whether and how BDNF-trkB
signaling in the DRG is involved in the process of inflammatory pain.
Methods: We used complete Freund’s adjuvant- (CFA-) induced and tumor necrosis factor-a- (TNF-a-) induced
inflammation in rat hindpaw as animal models of inflammatory pain. Quantification of protein and/or mRNA levels of
pain mediators was performed in separate lumbar L3-L5 DRGs. The cellular mechanism of TNF-a-induced BDNF and/
or trkB receptor expression was examined in primary DRG cultures collected from pooled L1-L6 DRGs. Calcitonin
gene-related peptide (CGRP), BDNF and substance P release were also evaluated by enzyme immunoassay.
Results: CFA injection into rat hindpaw resulted in mechanical hyperalgesia and significant increases in levels of
TNF-a in the inflamed tissues, along with enhancement of BDNF and trkB receptor as well as the pain mediators
CGRP and transient receptor potential vanilloid receptor subtype 1 (TRPV1) in DRG. Direct injection of TNF-a into rat
hindpaw resulted in similar effects with retrograde transport of TNF-a along the saphenous nerve to DRG during
CFA-induced inflammation. Primary DRG cultures chronically treated with TNF-a showed significant enhancement of
mRNA and protein levels of BDNF and trkB receptor, BDNF release and trkB-induced phospho-ERK1/2 signal.
Moreover, CGRP and substance P release were enhanced in DRG cultures after chronic TNF-a treatment or acute
BDNF stimulation. In addition, we found that BDNF up-regulated trkB expression in DRG cultures.
Conclusions: B a s e do no u rc u r r e n te x p e r i m e n t a lr e s u l t s ,w ec o n c l u d et h a ti n f l a m m a t i o na n dT N F - a up-regulate the
BDNF-trkB system in DRG. This phenomenon suggests that up-regulation of BDNF in DRG may, in addition to its post-
synaptic effect in spinal dorsal horn, act as an autocrine and/or paracrine signal to activate the pre-synaptic trkB receptor
and regulate synaptic excitability in pain transmission, thereby contributing to the development of hyperalgesia.
Background
Inflammation and pain largely share a common course of
progression; patients with inflammation may suffer hyper-
algesia and/or allodynia to various mechanical, thermal
and chemical stimuli [1]. Inflammation results in an array
of chemical mediators being released and triggering
immune cell accumulation in the damaged area. Those
activated immune cells further release pro-inflammatory
cytokines and neurotrophins including nitric oxide (NO),
interleukin-1b (IL-1b), interleukin-6 (IL-6), tumor necrosis
factor-a (TNF-a) and nerve growth factor (NGF) [1-3]
producing either central or peripheral sensitization [3-5].
TNF-a is a potent pro-inflammatory cytokine that has
been used frequently in laboratory studies to evoke inflam-
matory reactions. TNF-a activates the release of many
cytokines, such as IL-1b, IL-6 and IL-8, and participates in
the development of inflammatory hyperalgesia mainly
through its receptor, TNFR1 and TNFR2 [6-8]. TNF-a-
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largely mediated by TNFR1 [9-11].
Neurotrophins like NGF, neurotrophin 3/4 (NT-3/4)
and brain-derived neurotrophic factor (BDNF) can be
released from DRG, acting to either support neuronal
development [12] or participate in the induction of
hyperalgesia [3]. NGF is recognized to play a potent role
in the development of neurogenic pain by inducing
hyperalgesia [5,13]. After release from immune cells,
NGF up-regulates the expression of proteins involved in
inflammatory pain transmission, TRPV1, BDNF, calcito-
nin gene-related peptide (CGRP) and substance P in the
DRG via tyrosine protein kinase A (trkA) receptor
[2,3,14-17]. BDNF is expressed and synthesized in small-
to medium-sized DRG neurons and co-expressed with
trkA along with CGRP and substance P [18,19]. Hence,
BDNF can be released in response to peripheral NGF via
trkA stimulation and is known as a nociceptive modula-
tor for both pain perception and sensitization at both
spinal and supraspinal levels [18]. In particular, nocicep-
tor-drived BDNF has been demonstrated to regulate
acute and inflammatory pain [20]. Tyrosine protein
kinase B (trkB) is a high affinity BDNF receptor [18].
Recent ultrastructural evidence indicates that trkB recep-
tor is not only expressed in post-synaptic neurons but
also localizes to pre-synaptic terminals in spinal lamina II
[21]. BDNF in spinal cord lamina II is a neuromodulator
of nociception at synapses. Recent studies indicate that
BDNF acts on pre-synaptic trkB receptors to increase the
frequency of glutamatergic EPSCs in spinal dorsal horn of
complete Freund’s adjuvant- (CFA-) treated rats [22,23].
Hence, BDNF-induced thermal hyperalgesia can be inhib-
ited by intrathecally applied NMDA receptor antagonist
D-APV [24]. Further, it has been found that trkB phos-
phorylation is increased under noxious mechanical, ther-
mal or chemical stimulation [25]. This effect is tightly
associated with extracellular signal-regulated kinase (ERK)
and phospholipase C (PLC)/phosphoinositide-3 kinase
(PKC) signals [18].
The aim of this study was to investigate the role of
BDNF-trkB within DRG during the progression of inflam-
matory pain, specifically focusing on whether and how the
pro-inflammatory cytokine TNF-a influences trkB expres-
sion and signaling. To accomplish this aim, we used CFA-
induced inflammation in rats as a chronic pain model to
examine neurochemical changes in lumbar DRG. Levels of
t h ep r o - i n f l a m m a t o r yc y t o k i n eT N F - a were first deter-
mined in the inflamed tissues. Consequently, a set of ani-
mals was injected with TNF-a directly into hindpaw to
assess inflammatory pain responses. In addition, we used
DRG primary cultures and treated with TNF-a for
mechanistic and functional studies. We demonstrate that
BDNF and trkB receptors are up-regulated in DRG of
CFA- and TNF-a-induced inflammatory pain models. In
addition, retrograde transport of TNF-a was observed in
the CFA-induced inflammation model. Both trkB recep-
tors and trkB-induced ERK signaling were increased after
chronic TNF-a-treatment in DRG primary cultures.
Furthermore, both CGRP and substance P release were
enhanced after chronic TNF-a pre-treatment or acute
BDNF administration in DRG cultures. We conclude that
experimental arthritis and TNF-a initiate a BDNF-trkB
feed-forward pathway in peripheral sensory neurons, and
this up-regulation of BDNF-trkB system may participate
in pain sensitization.
Methods
Animals
Male Sprague-Dawley (SD) rats (BioLASCo Taiwan Co.,
Ltd) weighing 250-280 g (for inflammatory animal
model) or 3-4 weeks of age (for primary culture) were
used in the current study. After arrival, animals were
acclimatized to the room with controlled temperature
(22 ± 2°C), air humidity (50 ± 10%) and 12 hours day-
night cycle (light on at 7:00 AM) for at least 7 days before
experimentation. The animals were housed 2 or 3 per
cage with food (Western Lab 7001, Orange, CA, USA)
and water ad libitum. The animal handling and drug
treatments were performed in strict accordance with the
NIH Guide for the Care and Use of Laboratory Animals,
and all procedures were approved by the Animal Care
Committee of Chang-Gung University.
Chemicals
CFA (Sigma, St. Louis, MO, USA) was freshly prepared
(1:1 with saline containing 0.05 mg heat-killed and dried
Mycobacterium tuberculosis and paraffin oil mixed in a
water-in-oil emulsion). Recombinant rat TNF-a protein
(R & D systems, Minneapolis, MN, USA) was reconsti-
tuted with phosphate buffered saline (PBS)/0.1% bovine
serum albumin (BSA). Recombinant human BDNF protein
(Abcam, Cambridge, MA, USA) was reconstituted with
ddH2O. NGF 2.5S (Chemican, Temecula, CA, USA) was
reconstituted with PBS.
Animal model of inflammatory pain
To produce an in vivo model of inflammatory pain, ani-
mals were anesthetized with isoflurane and locally
injected with CFA, TNF-a or vehicle. In the CFA-treated
group, animals were injected with 100 μl CFA into the
right hindpaw with the contralateral side serving as an
untreated control. Other animals received saline injection
in the hindpaw to serve as a vehicle control. In the TNF-
a-treated group, animals received 500 ng TNF-a (30 μl)
in the hindpaw twice daily for three consecutive days, fol-
lowed by daily mechanical von Frey tests. Lumbar L3~L5
DRGs or hindpaw tissues were collected 72 hours after
CFA or TNF-a injection and samples of DRG were
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TNF-a (ipsilateral), control (contralateral) and saline
groups.
Pain threshold test
Mechanical hyperalgesia was measured by the von Frey
method [26]. The test was performed daily in CFA- or
TNF-a-treated rats for a period of up to three days. To
perform the von Frey test, rats were placed in a clear plexi-
glass box (20 × 19 × 20 cm) on an elevated mesh screen. A
calibrated von Frey rigid tip (Electronic von Frey Anesthe-
siometer, IITC Life Science, USA) was applied to the plan-
tar surface of each hindpaw in a series of logarithmically
ascending forces. The responses were recorded in grams
of paw withdrawal averaged over three to five applications
referred to as mechanical pain threshold. The interval of
each application was 5 min.
Primary DRG culture
Bilateral lumbar L1-L6 DRGs were dissected from 3-4-
week-old SD rats. DRG tissues were digested with 1 mg/
ml collagenase (Sigma) at 37°C for 30 min and then incu-
bated with 0.25% (v/v) trypsin-EDTA (Biological Indus-
tries, Israel) at 37°C for 30 min. Tissues were centrifuged
at 300 × g for 5 min and then re-suspended in DMEM/
F12 medium (repeated three times). Next, tissues were
manually triturated approximately sixty times using a
flame-polished Pasteur pipette. The dissociated cells were
suspended in DMEM/F12 medium containing 10% fetal
calf serum, 100 μg/ml penicillin/streptomycin and 1 mM
sodium pyruvate and plated onto poly-L-lysine-coated
plates. Medium was replaced the following day with the
addition of 10 μM Ara-C and 100 ng/ml NGF and chan-
ged every two days thereafter. After cell plating for two
days, all drugs (TNF-a, BDNF or NGF) were added for the
designated time periods and samples (medium or cultured
cells) were all collected by the end of each experiment
(including basal control).
Western blot
All samples were sonicated in 1% (w/v) sodium dodecyl
sulfate (SDS) and heated to 100°C for 5 min. Protein con-
centration was determined by the Coomassie blue
method with bovine serum albumin as standard. Equal
a m o u n t so fp r o t e i n s( 1 0 - 4 0μg) were separated by 10%
SDS-polyacrylamide gel electrophoresis and transferred
onto a polyvinylidene difluoride (PVDF) membrane
(Millipore Corporation, Bedford, MA, USA) using
200 mA for 70 min at 4°C. Immunoblots were first
blocked with 5% (w/v) non-fat milk for 1 hour, followed
by incubation overnight with specific primary antibody.
The antibodies used were anti-b-actin antibody (1:1000;
Sigma), anti-phospho-p44/42 MAP kinase (Thr202/
Tyr204) antibody (anti-phospho-ERK1/2, 1:1000; Cell
Signaling, Beverly, MA, USA). On the second day, blots
were incubated with secondary antibody conjugated with
HRP (1:2000-1:10,000, GE Healthcare, UK) for 1 hour.
After another 3 × 10 min washes with TBS-T buffer, the
substrate solution (Amersham ECL kit) was applied for 1
min. The enhanced chemiluminescence signal was
detected with X-ray film (Kodak, X-OMAT) and quanti-
fied by laser scanning densitometry (Molecular
Dynamics, Sunnyvale, CA). Signals were normalized to b-
actin.
Quantitative real-time PCR
Total RNA was isolated from cultured DRG neurons or
tissues using TRIzol
® reagent (Invitrogen, Carlsbad, CA,
USA) according to the manufacturer’sp r o t o c o l .T h e
mRNA was transcribed to cDNA via reverse transcriptase
(HT BioTechnology, England UK). The cDNA for corre-
sponding targets was measured by quantitative real-time
PCR using a PE Applied Biosystems prism model 7000
sequence detection instrument (Applied Biosystems, Fos-
ter City, CA, USA). The PCR program was: 95°C for 10
min then 95°C for 15 sec and 60°C 30 sec for 40 cycles.
SYBR (Invitrogen) was used as fluorescent dye and ROX
as reference dye. The primer sequences are as follows:
18S-forward, 5’ GCT GTG GTC CAA GGC CAT TTT 3’;
18S-reverse, 5’ CCG AGT TAC TTT TCC CCA GAT
GAC 3’[GenBank: NM_000996]; TRPV1-forward, 5’ GCG
AGT TCA AAG ACC CAG AG 3’; TRPV1-reverse, 5’
GGC ATT GAC AAA CTG CTT CA 3’[GenBank:
NM_031982]; trkB.FL-forward, 5’ A A GA T CC T GG T G
GCC GTG AAG A 3’; trkB.FL-reverse, 5’ CGG CTT CGC
G A TG A AA G TC C TT3 ’[GenBank: NM_012731];
BDNF-forward-1, 5’ CAA GGC AAC TTG GCC TAC CC
3’; BDNF-reverse-1, 5’ GAG CAT CAC CCG GGA AGT
GT 3’;B D N F - f o r w a r d - 2 ,5 ’ TTA CCT GGA TGC CGC
A A AC A3 ’; BDNF-reverse-2, 5’ TGG CCT TTT GAT
ACC GGG AC 3’ [GenBank: NM_012513]; CGRP-for-
ward, 5’ AAC CTT AGA AAG CAG CCC AGG CAT G
3’;C G R P - r e v e r s e ,5 ’ G T GG G CA C AA A GT T GT C C
TTC ACC A 3’[GenBank: M11597]. Threshold cycle, Ct,
which correlates inversely with the target mRNA levels,
was measured. ABI Prism Primer Express was used to
design the specific gene primers. After normalization to
18S values, data were expressed as percentage of corre-
sponding controls.
Immunohistochemistry (IHC) for tissue sections
SD rats were sacrificed by decapitation; L3-L5 DRGs were
removed and post-fixed in 4% (w/v) paraformaldehyde
solution for 48 hours at 4°C, then cryo-protected with 20%
(w/v) sucrose in potassium phosphate buffer saline (KPBS,
KH2PO4 3.3 mM, K2HPO4 21.9 mM, NaCl 154 mM)
Lin et al. Journal of Neuroinflammation 2011, 8:126
http://www.jneuroinflammation.com/content/8/1/126
Page 3 of 22overnight at 4°C. IHC images were collected from 14 μm
sections prepared using a freezing microtome (LEICA
CM3050S, Bannockburn, IL, USA).
Tissue sections were rinsed twice with KPBS. Endogen-
ous peroxidase was quenched by pre-treating the sections
with 0.03% (v/v) H2O2. The sections were then rinsed with
KPBS followed by pretreatment with 1% (w/v) sodium tet-
rahydridoborate for 5 min. Afterward, the sections were
incubated in primary antibody in 2% (w/v) normal goat
serum/0.3% (v/v) TX-100/KPBS at 4°C for 48 hours. The
antibodies used were anti-trkB antibody (1:2000; Santa
Cruz, Santa Cruz, CA, USA), anti-BDNF antibody (1:1000;
Abcam), anti-CGRP antibody (1:8000; Chemicon). After-
ward, sections were incubated with 1:200 biotinylated goat
anti-rabbit IgG secondary antibody for 1 hour. Immunor-
eactivity was visualized by the avidin-biotin complex
method (Vector Lab., Burlingame, CA, USA). After incu-
bating with the avidin-biotin complex for 1 hour, sections
were developed using 3, 3’-diaminobenzideine (DAB;
Sigma) and nickel ammonium sulfate in KPBS. Sections
were mounted onto gelatin-coated slides, dehydrated
through a serial alcohol gradient, degreased with xylene
and then covered slipped with Entellan (Merck, Germany).
Co-localization of BDNF and TNFR1 was evaluated by
immunofluorescent double stain. Primary antibodies (anti-
BDNF, 1:200; Abcam and anti-TNFR1, 1:20; Santa Cruz)
w e r em i x e da n di n c u b a t e da t4 ° Cf o r7 2h o u r s .A f t e r
washed with KPBS, sections were incubated with second-
ary antibodies (Rodamine-conjugated goat-anti-mouse and
Dylight 488-conjugated goat-anti-rabbit, 1:200, Jackson
ImmunoResearch, West Grove, PA, USA) for 1 hour at
room temperature. Sections were then incubated with
1:1000 DAPI (4’,6-diamidino-2-phenylindole, Roche, Swit-
zerland) for 5 min before mounting with glycerol. Signals
of immunofluorescent stain were observed by fluorescence
microscope.
Immunocytochemistry for cultured cells
Cultured DRG neurons were fixed with 2% (w/v) parafor-
maldehyde solution (2% paraformaldehyde containing
0.3% TX-100, pH 7.2) for 30 min. Cells were rinsed with
PBS/0.3% TX-100 following blocking with 2% normal goat
serum in PBS/0.3% TX-100 for 30 min. Cells were then
incubated in primary antibody in PBS/0.3% TX-100/2%
goat serum at 4°C for 48 hours. The antibodies used were
anti-trkB antibody (1:2000), anti-BDNF antibody (1:1000),
anti-CGRP antibody (1:8000). TrkB staining was visualized
via immunofluorescence. After rinsing three times, cells
were incubated with FITC-conjugated goat anti-rabbit IgG
secondary antibody (1:200, Jackson ImmunoResearch) for
1 hour. Afterward, cells were then incubated with 1:1000
DAPI for 5 min before mounting with glycerol. Co-locali-
zation of TNFR1 and phospho-ERK were evaluated by
immunofluorescent double stain. Primary antibodies (anti-
TNFR1, 1:20 and anti-phospho-ERK1/2, 1:250) were
mixed and incubated at 4°C for 72 hours. After wash with
PBS, secondary antibodies, Rodamine-conjugated goat
anti-mouse and Dylight 488-conjugated goat anti-rabbit
(1:200, Jackson ImmunoResearch), were also mixed
together and added for 1 hour. Slides were then incubated
with 1:1000 DAPI for 5 min before mounting with gly-
cerol. Immunofluorescent stain signal was observed by
fluorescence microscope. On the other hand, BDNF and
CGRP staining were visualized via avidin-biotin complex
method. Similar to immunohistochemistry, endogenous
peroxidase was quenched by pre-treating the sections with
0.03% H2O2 followed by pretreatment with 1% sodium tet-
rahydridoborate. After incubating with primary antibody
and rinsing with PBS/0.3% TX-100, the cells were incu-
bated in 1:200 biotinylated goat anti-rabbit IgG secondary
antibody for 1 hour and rinsed with PBS. After incubation
with avidin-biotin complex for 1 hour, ABC reaction was
performed with a mixture of DAB and nickel ammonium
sulfate. Cells were mounted on slides, dehydrated, and
cover-slipped with mounting solution. The color of preci-
pitate formed by DAB was monitored microscopically.
Enzyme immunoassay (EIA)
The release of BDNF, CGRP and substance P were deter-
mined using BDNF Emax
® ImmunoAssay system (Pro-
mega, Madison, WI, USA), CGRP EIA kit (SPIbio, France)
or substance P EIA kit (Cayman, Ann Arbor, Michigan,
USA), respectively. For BDNF assay, after 5 nM TNF-a
treatment for 48 hours, medium of DRG cultures were
collected. The cells were lysised, sonicated and then cen-
trifuged at 10,000 × g for 15 min. The supernatants were
analyzed and represented as total BDNF content. For
CGRP and substance P EIA assay, after 5 nM TNF-a
treatment for 48 hours, culture medium were replaced by
a fresh medium and allowed cells stable for 2 hours. After-
wards, 400 ng/ml BDNF was added for 30 or 60 min and
the supernatant was collected and analyzed immediately
according to the manufacturer’s protocols. The microplate
was read at 405 nm (yellow color) in an enzyme-linked
immunosorbent assay (ELISA) plate reader (ASAY micro-
plate reader, expert 96, Austria).
The amount of TNF-a in rat hindpaw or DRG was eval-
uated using a rat TNF-a EIA kit (R&D system). After
CFA-injection for 72 hours, rat hindpaw or L3~L5 DRGs
were isolated and analyzed immediately. Tissues were col-
lected in PBS solution containing proteinase inhibitors
leupeptin, aprotenin and PMSF (Sigma). After homogeni-
zation, tissues were centrifuged at 10,000 × g,4 ° Cf o r
20 min and supernatants were collected. Blood samples
were withdrawn from the animals’ trunks into a blood col-
lection tube containing 5.4 mg K2 EDTA and centrifuged
at 1,000 × g for 10 min in the room temperature to collect
the serum. Samples were analyzed immediately according
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TNF-a was determined by the absorbance at 450 nm with
reference filter at 540 nm.
TNF-a retrograde transport tracing
Recombinant rat TNF-a protein (10 μg) was labeled with
Alexa Fluor 488 (Molecular Probes, Invitrogen) according
to the manufacturer’s protocols. Animal received Alexa
Fluor 488-TNF-a (25 μl) in CFA pre-treated hindpaw
24 hours before sacrifice (72 hours after CFA injection).
Alexa Fluor 488 (25 μl) injection in CFA pre-treated hind-
paw served as control. After injection, ipsilateral saphe-
nous nerve was isolated immediately and monitored under
fluorescence microscope. The fluorescent signals in the
saphenous nerve were separately measured in three seg-
ments: distal (0.5 cm from the heel), middle (1.3 cm from
the heel) and proximal (2 cm from the heel).
TUNEL reaction
Cell apoptosis was evaluated using an in situ cell death
detection kit (TUNEL reaction, Roche, Germany), follow-
ing the manufacturer’s protocols, DRG primary cultures
were fixed with 2% paraformaldehyde for 1 hour, then
incubated with 0.1% Triton X-100/0.1% sodium citrate for
2 min on ice. Afterwards, the cultures were washed with
PBS and then treated with 50 μl TUNEL reaction mixture
(containing green Fluorescein) at 37°C for 60 min in the
dark. After enzyme reaction, cultures were washed with
PBS and double stained with DAPI (1:1,000) for 5 min.
Numbers of apoptotic cells were evaluated by observation
under a fluorescence microscope.
Data analyses and statistics
ImageJ (NIH, Bethesda, MD, USA) software was used to
quantify the immunostaining images. A threshold was set
by ImageJ to define the positive neurons among different
experiments of the same study. For DRG immunostain-
ing, three different sections (spacing 250~300 μm) were
selected to calculate the total number of positive neurons
and expressed as the percentage of positive neurons rela-
tive to the total number of neurons visualized in DRG
sections. For the data in Table 1, small, medium and
large DRG neurons were identified and counted based on
the diameter of the neuron: small neurons < 25 μm; med-
ium neurons 25 to 40 μm; and large neurons > 40 μm.
The results were calculated by two methods: 1) percen-
tage of trkB-positive neurons in specific categories (small,
medium, or large) relative to the total number of neurons
in DRG sections; 2) percentage of trkB-positive neurons
in specific categories relative to the total number of trkB-
positive neurons in the DRG sections.
All data were analyzed with GraphPad InStat (GraphPad
Software, San Diego, CA, USA). Results are expressed as
mean ± SEM. The data were analyzed by one-way
ANOVA followed by Tukey multiple comparisons test or
un-paired Student’s t-test. A value of p < 0.05 was consid-
ered significant.
Results
Establishment of a CFA-induced inflammation animal
model
SD rats receiving 100 μl CFA in the intraplantar surface
developed mono-arthritis within 72 hours. CFA-injected
hindpaw appeared swollen and enlarged by the third day
after injection (Figure 1B). In contrast, the non-injected
contralateral hindpaw and saline injected controls dis-
played no significant size change (Figure 1A).
To measure pain threshold, mechanical hyperalgesia
was assessed in three experimental groups via daily von
Frey testing. As shown in Figure 1D, the threshold of
mechanical stimulation progressively decreased with time
after CFA injection. Statistically significant differences
compared to basal level were found on the second and
third days. No inflammatory signs were observed in the
saline-injected group within 72 hours (data not shown).
This result is similar to those of the non-injected contral-
ateral hindpaw.
To determine if the pro-inflammatory cytokine TNF-a
was involved in CFA-induced hyperalgesia, tissue con-
tent of TNF-a was measured in rat hindpaw, DRG and
serum 72 hours after CFA-injection by a TNF-a EIA
kit. As shown in Figure 2, TNF-a levels increased signif-
icantly in CFA-injected hindpaw as compared with con-
tralateral hindpaw controls (1.28 pg/mg for control vs.
24.78 pg/mg for TNF-a-treated group). Levels of TNF-a
in L3-L5 DRGs and serum did not reach the EIA detec-
tion limit (data not shown).
Further, to test whether TNF-a is involved in the
development of inflammatory hyperalgesia, TNF-a was
injected directly into rat hindpaw twice daily over a con-
tinuous three day period with mechanical hyperalgesia
measured via von Frey. Similar to the CFA-injected ani-
mals, the hindpaw receiving TNF-a injection exhibited
swelling (Figure 1C) accompanied by a time-dependent
decrease in mechanical pain threshold (Figure 1E).
Table 1 Quantitative measurements of trkB-positive
neurons in L3 DRG after CFA injection
Small Medium Large
Control
% to total neurons 10.19 ± 1.27 2.15 ± 0.38 0.85 ± 0.33
% to total trkB
+ neurons 77.66 ± 3.15 16.42 ± 2.17 5.92 ± 2.34
CFA
% to total neurons 20.7 ± 1.31*** 4.94 ± 0.68** 1.63 ± 0.25
% to total trkB
+ neurons 76.84 ± 19.3 17.35 ± 1.42 5.81 ± 0.71
Data expressed as mean ± SEM and analyzed using an un-paired Student’s
t-test, **p < 0.01, ***p < 0.001; compared to corresponding control (N = 9 per
group).
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Figure 1 Appearance of the rat hindpaw and von Frey hyperalgesia test after intraplantar CFA or TNF-a injection. Seventy-two hours
after injection of CFA, TNF-a or saline (control) into the right hindpaw of SD rats, we observed the hindpaw (A-C). Daily hyperalgesia testing
was carried out for three days (D, E). Saline: 0.9% NaCl (ipsilateral) injection. Control (contra): contralateral to CFA or TNF-a. CFA (ipsi): CFA (100
μl) injected. TNF-a (ipsi): 500 ng TNF-a (30 μl) injected. Data were analyzed using one-way ANOVA followed by Tukey test and are expressed as
mean ± SEM. **p < 0.01, ***p < 0.001; compared to basal (SD rats, N = 5 per group for CFA injection and N = 3 per group for TNF-a injection).
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DRG after CFA injection
To identify the underlying biochemical changes, rats
were sacrificed 72 hours after CFA injection and L3-L5
DRGs were individually isolated. The mRNA levels for
TRPV1, trkB, BDNF and CGRP were measured using
real-time PCR. 18S ribosome RNA was used as internal
control (Figure 3A). mRNA levels for TRPV1 and trkB
were significantly increased in L3 DRG after CFA injec-
tion. On the other hand, mRNA levels for TRPV1, trkB
and BDNF in L4 and L5 DRG after CFA injection showed
no change compared to contralateral controls. To con-
firm this result, a second set of BDNF primers was used
to analyze the tissues; however the results remained the
s a m e ,i . e .n os i g n i f i c a n td i f f erence between control and
CFA-treated groups in L3-L5 DRGs (data not shown).
Further, CGRP mRNA expression did not change in L3-
L5 DRG segments after CFA treatment.
Protein levels of BDNF, trkB and CGRP were also
monitored via IHC detection in L3, L4 and L5 DRGs
after CFA injection for 72 hours (Figure 3B-H). Protein
expression was evaluated by counting numbers of posi-
tive neuron in DRG sections (Figure 3B). The results
showed that the number of trkB receptor-positive neu-
rons was significantly increased in both L3 and L5
DRGs, while the number of CGRP-positive neurons was
increased significantly in all L3-L5 DRGs after CFA
injection. Levels of BDNF protein increased significantly
only in L3. Quantitative measurements of immunoreac-
tivity in L3 sections showed that after CFA injection,
the numbers of BDNF-, trkB- and CGRP-positive neu-
ron were enhanced 3.18, 2.68 and 2.42 fold, respectively
(Figure 3B).
To explore whether CFA-induced trkB over-expression
occurs in a particular type of DRG neuron, trkB-positive
neurons were separately counted based on the diameter
of the neuron (small, medium and large neurons) in L3
DRG. As shown in Table 1, the percentage of trkB-posi-
tive neurons relative to total neurons in DRG was
increased in small (p <0 . 0 0 0 1 )a n dm e d i u m( p = 0.0025)
neurons after CFA injection, with the percent increase of
trkB-positive neurons equally distributed in three differ-
ent size neuronal populations. It was noted that trkB
receptors were mainly expressed in small-sized neurons
(77.66% of control and 76.84% of CFA treated), moder-
ately expressed in medium-sized neurons (16.42% of con-
trol and 17.35% of CFA treated) but rarely expressed in
large-sized (5.92% of control and 5.81% of CFA treated)
DRG neurons.
The changes in expression of BDNF, trkB and CGRP
p r o t e i ni nL 3 - L 5D R G sw e r ea l s oe v a l u a t e d7 2h o u r s
after TNF-a injection (twice daily for three days) in the
hindpaw. Data are presented as percentage of positive
neurons in DRG. L3-L5 DRGs were counted separately.
As shown in Figure 4, the amounts of BDNF, trkB and
CGRP protein were significantly increased in L4 DRG.
Similarly, the amount of BDNF and CGRP protein was
enhanced in L3 and L5 DRGs, respectively. We found
that the elevation of either protein after TNF-a treatment
was less than that induced by CFA treatment (compared
from Figure 4A, L4 and Figure 3B, L3).
Previously, it was reported that under peripheral inflam-
matory conditions, TNF-a binds to TNFR1 and activates
inflammatory signals by retrograde transport to the DRG
[27]. Double fluorescent staining was thus used to test
whether BDNF and TNFR1 were co-localized in L3-L5
DRGs 72 hours after CFA injection. As shown in Figure 5,
BDNF protein was largely co-localized with TNFR1 and
the number of co-localized TNFR1 and BDNF cells was
significantly enhanced after CFA injection (Figure 5A).
We also found that TNFR1 protein is largely localized in
the cytoplasm (Figure 5B~G).
Up-regulation of BDNF-trkB in cultured DRG neurons after
TNF-a treatment
In order to investigate the cellular mechanism of inflam-
matory responses, primary DRG cultures were used (col-
lected from bilateral L1~L6 DRGs of 3~4 week old SD
rats). Since we observed significantly increased TNF-a in
rat hindpaw after CFA injection, and mechanical hyperal-
gesia develops in rats after direct treatment with TNF-a,
t h ep r o - i n f l a m m a t o r yc y t o k i n eT N F - a was applied to
mimic the in vivo inflammatory condition. TNF-a
(5 nM) was added to the culture medium at 3 days in
vitro (DIV) and maintained for up to 48 hours. As shown
in Figure 6A, mRNA levels of TRPV1, BDNF and trkB
were differentially enhanced after TNF-a treatment
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Figure 2 Levels of TNF-a in hindpaw after intraplantar CFA
injection. Seventy-two hours after CFA injection, tissues from both
hindpaw were collected and analyzed immediately by TNF-a EIA kit.
Control (contra): contralateral to CFA, non-injected. CFA (ipsi):
injected. Data are expressed as mean ± SEM and were analyzed
using an un-paired Student’s t-test. ***p < 0.001; compared to
control (SD rats, N = 7 per group).
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Figure 3 Expression of TRPV1, trkB, BDNF and CGRP in DRG after intraplantar CFA injection. Seventy-two hours after CFA injection, mRNA
and protein levels of TRPV1, trkB, BDNF and CGRP were measured in L3-L5 DRGs. (A) mRNA levels were measured by real-time PCR. Values were
normalized to 18S values, and are presented as percent of corresponding controls. Data are expressed as mean ± SEM and were analyzed by
un-paired Student’s t-test. *p < 0.05; compared to corresponding control groups (N = 3~6 per group, pooled from a total of 12 rats). (B)
Quantitative measurements of trkB, BDNF and CGRP immunoreactivity in DRG sections. Protein levels were detected by the standard
immunohistochemical ABC method. Data are presented as percentage of immuno-positive neurons in L3-L5 DRGs. (C-H) Photomicrographs
illustrate the immunoreactivity of trkB, BDNF and CGRP in L3 DRG sections. (C-E), control group; (F-H), CFA group. Scale bars, 50 μm. Data are
expressed as mean ± SEM and were analyzed using an un-paired Student’s t-test. *p < 0.05, **p < 0.01, ***p < 0.001; compared to
corresponding controls (contralateral to CFA injection). N = 9 per group. Control, ctr (contra): contralateral to CFA, non-injected. CFA (ipsi):
injected.
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Figure 4 Amount of trkB, BDNF and CGRP protein in DRG after intraplantar TNF-a injection. After TNF-a injections (twice daily for three
days), levels of trkB, BDNF and CGRP were measured in L3-L5 DRGs. Protein expression was detected by the standard immunohistochemical ABC
method. (A) Quantitative measurements of trkB, BDNF and CGRP immunoreactivity in DRG sections. Data are presented as percentage of
immuno-positive neurons in L3-L5 DRGs. (B-G) Photomicrographs illustrate the immunoreactivity of trkB, BDNF and CGRP in L4 DRG sections. (B-
D), control group; (E-G), TNF-a group. Scale bars, 50 μm. Control, ctr (contra): contralateral to TNF-a. TNF-a (ipsi): injected. Data are expressed as
mean ± SEM and were analyzed using an un-paired Student’s t-test. *p < 0.05, **p < 0.01; compared to corresponding controls (contralateral to
TNF-a injection). N = 9 per group.
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Page 9 of 22between 6 and 12 hours. In contrast, mRNA levels of
CGRP remained unchanged after TNF-a treatment, simi-
lar to the results obtained from DRG of hyperalgesic ani-
mals (Figure 3A). Similarly, IHC analyses further revealed
that TNF-a addition progressively increased BDNF, trkB
and CGRP protein in DRG cultures after 24 and 48 hours
(Figure 6B - 6J).
To further confirm the impact of TNF-a on BDNF-
trkB system in the DRG, TNF-a-induced BDNF release
was evaluated by BDNF EIA. After treatment with TNF-
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Figure 5 Co-localization of BDNF and TNFR1 in the L3-L5 DRGs. Immunoreactivity was detected by double immunofluorescent stain. L3-L5
DRGs were collected after CFA injection for 72 hours. BDNF is shown by green fluorescence and TNFR1 is shown by red fluorescence. (A) Bar
graph representing quantitative measurement of numbers of cells displaying TNFR1 and BDNF co-localization. Data are expressed as mean ±
SEM and were analyzed using an un-paired Student’s t-test. ***p < 0.001 (N = 9 per group); compared to control. (B-D) Photomicrographs
illustrate the immunoreactivity of BDNF (B) and TNFR1 (C) in the L3 DRG sections of control group. (D) Merged image of (B) and (C). (E-G)
Photomicrographs illustrate the immunoreactivity of BDNF (E) and TNFR1 (F) in L3 DRG sections of the CFA group. (G) Merged image of (E) and
(F). Inserts illustrate BDNF and TNFR1 signals that co-localized in a DRG neuron. Wide arrow, co-localized BDNF and TNFR1; narrow arrow, TNFR1;
arrowhead, BDNF. Scale bars, 50 μm.
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Figure 6 Amount of TRPV1, trkB, BDNF and CGRP expression in DRG cultures after TNF-a treatment. (A) Levels of TRPV1, trkB, BDNF and
CGRP mRNA in DRG cultures (N = 3-7 per group). mRNA expression levels were assessed by real-time PCR after a 5 nM TNF-a treatment for 6
to 48 hours, and the results were normalized to 18S values. Data are expressed as mean ± SEM, presented as percentage of basal (no drug
treatment) and were analyzed using one-way ANOVA followed by Tukey test. *p < 0.05, **p < 0.01, ***p < 0.001; compared to corresponding
basal groups. (B-J) Photomicrographs illustrate the immunoreactivity of BDNF, trkB and CGRP in DRG cultures. The amount of protein was
detected by immunofluorescent stain or the immunohistochemical ABC method after a 5 nM TNF-a treatment for either 24 or 48 hours in DRG
cultures. (B, E, H) Basal protein expression (no drug treatment). (C, F, I) TNF-a treatment for 24 hours. (D, G, J) TNF-a treatment for 48 hours.
Scale bars, 50 μm.
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Page 11 of 22a for 24 or 48 hours, BDNF release and expression were
analyzed in supernatant medium and cultured cells,
respectively. The results show that BDNF release was
significantly enhanced after TNF-a treatment for 48
hours (Figure 7). Total BDNF content in DRG cultures
was also increased 24 and 48 hours after TNF-a treat-
ment (Figure 7).
Expression of BDNF-trkB in cultured DRG neurons after
neurotrophin treatment
It has been reported that NGF increases the expression of
BDNF in peptidergic small neurons in DRG and the
release of BDNF was targeted to spinal cord lamina II
[17,18]. In order to understand the impact of neurotro-
phins on inflammation-related proteins, NGF and BDNF
(100 ng/ml) were individually applied to DRG cultures for
up to 96 hours (Figure 8). Levels of TRPV1, BNDF, trkB
and CGRP mRNA were then quantified via real-time PCR.
The results show that NGF induced a significant time-
dependent increase in mRNA levels of TRPV1, BDNF and
CGRP (Figure 8A). On the other hand, BDNF had no
effect on mRNA expression of TRPV1 and CGRP, but sig-
nificantly up-regulated the mRNA expression of trkB in a
time-dependent manner (Figure 8B).
TrkB receptor-mediated ERK1/2 signaling in DRG cultures
after TNF-a treatment
To test the functional significance of TNF-a-dependent
trkB receptor up-regulation, trkB-mediated signaling was
evaluated in DRG cultures. BDNF (400 ng/ml) was acutely
applied (0, 5, 10, 20, 40 min) to DRG cultures after the
cells were treated with 5 nM TNF-a for 48 hours, and
then the downstream signals of phospho-ERK were mea-
sured by immunefluorescent stain. Further, to determine if
TNF receptor co-localized with phospho-ERK signals,
double fluorescent stain was employed. The results clearly
show that phospho-ERK is enhanced after acute BDNF
treatment for 10 min and is further increased by 48 hours
of TNF-a pre-treatment (Figure 9B, 9E). Morphological
results also reveal that a significant amount of BDNF-
evoked phospho-ERK signal is co-expressed with TNFR1,
and this occurred mainly in the cytoplasm (Figure 9D,
9G). A complete profile of time-dependent, BDNF-evoked
phospho-ERK signal for both control and TNF-a treated
groups was evaluated. Quantitative measurements of fluor-
escent intensity showed that BDNF induced a clear time-
dependent enhancement in phospho-ERK signal in the
TNF-a pre-treated group, but only a trend toward an
increase in the control group (Figure 9A; representative
photomicrographs are shown in Figure 10). Because
TNF-a pre-treatment elevated basal phospho-ERK, we re-
analyzed the data by normalization to corresponding con-
trols, and these results display a similar profile, i.e. BDNF-
induced phospho-ERK signals were enhanced in the
TNF-a pre-treated group as compared to control (a signif-
icant level was reached at 20 min post-BDNF treatment;
data not shown). In addition, phospho-ERK1/2 signals
were analyzed by western blot of DRG cultures. These
results show that BDNF-evoked phospho-ERK1 and phos-
pho-ERK2 signals were both increased time-dependently
after TNF-a pre-treatment (up to 20 min) and that this
increase is more pronounced than that seen in controls
(Figure 11). It is also noticed that basal phospho-ERK1/2
were decreased in the TNF-a pre-treated group in this
analysis (Figure 11). No apoptotic cells were identified by
TUNEL analysis after 5 nM TNF-a treatment for
48 hours or after acute BDNF administration (400 ng/ml)
for 10 or 40 min (Figure 12).
The effect of TNF-a pre-treatment and/or BDNF on CGRP
and substance P release in DRG cultures
To characterize the functional role of TNF-a-enhanced
BDNF-trkB signaling, CGRP and substance P were evalu-
ated in DRG cultures. Protein levels of CGRP were signifi-
cantly enhanced in DRG of either CFA-treated (Figure 3)
or TNF-a-treated hyperalgesic rats (Figure 4) and in TNF-
a-treated DRG cultures (Figure 6). To assess whether
TNF-a can induce CGRP release from cultured DRG, a
CGRP EIA was used. After treatment with 5 nM TNF-a
for 48 hours, a significant increase in basal CGRP release
(approximately 21.6%) was observed (Figure 13A). More-
over, to investigate if TNF-a-enhanced CGRP was func-
tionally associated with up-regulated trkB receptor, BDNF
(400 ng/ml) was applied to the culture medium for 30 or
60 min followed by CGRP detection. The results show
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Figure 7 TNF-a-induced BDNF content and release in DRG
cultures. After a 5 nM TNF-a treatment for 24 and 48 hours,
medium and lysed cells were collected and analyzed by BDNF EIA.
BDNF release represents basal or TNF-a-induced BDNF in the
culture medium; BDNF content means basal or TNF-a-induced
BDNF remaining in cultured DRG cells. Data are expressed as mean
± SEM and were analyzed using one-way ANOVA followed by Tukey
test, *p < 0.05; compared to corresponding basal groups (N = 5 per
group).
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Page 12 of 22that BDNF significantly enhanced basal CGRP release after
treatment for 30 min (approximately 12.1%) but could not
potentiate CGRP release in TNF-a-pre-treated DRG cul-
tures (Figure 13A).
Next, we examined whether BDNF could trigger
another nociception mediator, substance P release from
DRG, after TNF-a treatment. After treatment with 5 nM
TNF-a for 48 hours, an acute treatment with BDNF (400
ng/ml) was applied for 30 or 60 min and the amount of
substance P in the culture medium was analyzed using
an EIA kit. As shown in Figure 13B, basal substance P
release was significantly increased (approximately 65.8%)
after TNF-a treatment. Similar to the response of CGRP
release, basal substance P release was significantly
increased after BDNF stimulation for 60 min. However,
BDNF-evoked substance P release did not differ between
control and the TNF-a-pre-treated groups.
Retrograde transport of TNF-a in CFA-induced
inflammatory hindpaw
Retrograde axonal transport of TNF-a has been reported
in various pathological conditions [27,28]. For example,
retrograde transport of TNF-a is mediated by TNFR1 in a
carrageenan-induced inflammation animal model [27].
Hence, we examined whether TNF-a would undergo ret-
rograde transport from rat hindpaw along the saphenous
nerve during CFA-induced inflammation. After CFA injec-
tion, Alexa Fluor 488-conjugated TNF-a (30 μl) was
injected into rat hindpaw. Saphenous nerve was isolated
24 hours later. The results show green fluorescence in the
entire saphenous nerve of the Alexa Fluor 488-TNF-a-
treated group, but not in dye-only controls (Figure 14A).
Fluorescent intensity increased from distal (0.5 cm from
the heel) to proximal (2 cm from the heel). To test if
TNF-a transport possibly involves TNFR1, the amount of
TNFR1 was measured in DRG sections 72 hours after
CFA injection (in vivo) and in DRG cultures 48 hours
after TNF-a treatment (in vitro). As shown in Figure 14B
and 14C, the amount of TNFR1 protein was significantly
increased in DRG cultures after TNF-a treatment, but we
were not able to demonstrate a statistically significant
increase after CFA injection.
Discussion
Numerous studies have attempted to understand the
cellular mechanism underlying hyperalgesia and allody-
nia using a CFA-induced inflammation pain model. Our
study focused on the neurochemical changes in lumbar
DRG and clearly shows that protein levels of trkB,
BDNF and CGRP are significantly increased after ani-
mals develop hyperalgesia. Up-regulation of BDNF and
CGRP in DRG during inflammation is a well-known
phenomenon along with the consequent effect of post-
synaptic trkB over-expression in the dorsal horn of
spinal cord [18,29]. On the other hand, up-regulation of
trkB in DRG during progression of inflammation has
rarely been documented. Lee et al. (1999) reported that
mRNA of truncated trkB receptor increases in DRG
after CFA injection, but the full-length trkB receptor
does not. Further, Chien et al. (2007) reported that
BDNF, CGRP, trkA and p75
NTR are increased in DRG
after CFA treatment [30], while levels of trkB receptor
do not change. In addition to these reports, trkB expres-
sion and phospho-trkB signal have been found to be
enhanced in rat DRG after the insults of colitis or cysti-
tis as well as during spinal cord injury [31-33]. These
inconsistent findings imply that expression of DRG trkB
receptor during inflammation is variable, possibly due to
the complexity of chemical mediators that are recruited
in designated disease progression.
TRPV1 BDNF TrkB CGRP
0
50
100
150
200
250
300
Basal
24 hrs
48 hrs
72 hrs
96 hrs
* *
*
* *
%
 
o
f
 
B
a
s
a
l
(A) NGF  (B) BDNF 
TRPV1 TrkB CGRP
0
50
100
150
200
250 Basal
24 hrs
48 hrs
72 hrs * *
%
 
o
f
 
B
a
s
a
l
Figure 8 Expression of TRPV1, BDNF, trkB and CGRP mRNA in DRG cultures after NGF or BDNF treatment. (A) TRPV1, BDNF, trkB and CGRP
mRNA expression after 100 ng/ml NGF treatment, once daily for 24-96 hours. (B) TRPV1, trkB and CGRP mRNA expression after 100 ng/ml BDNF
treatment, once daily for 24-72 hours. Data are expressed as mean ± SEM, presented as percentage of basal (no drug treatment) levels, and were
analyzed using one-way AVOVA followed by Tukey test. *p < 0.05, **p < 0.01; compared to corresponding basal groups (N = 5~8 per group).
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Figure 9 BDNF-induced phospho-ERK signals and co-localization of phospho-ERK and TNFR1 after TNF-a treatment in DRG cultures.
Phospho-ERK signals were detected after 5 nM TNF-a pre-treatment for 48 hours followed by 400 ng/ml BDNF for 0-40 min. Phospho-ERK and
TNFR1 proteins were detected by double immunofluorescent stain. (A) Quantitative measurements of phospho-ERK fluorescent intensity in DRG
cultures. Data are presented as fluorescent intensity of immunopositive neurons, expressed as mean ± SEM, and were analyzed using one-way
ANOVA followed by Tukey test. **p < 0.01; compared to corresponding controls;
#p < 0.05,
###p < 0.001; comparison between TNF-a and time-
matched control groups (N = 9 per group). (B-G) After TNF-a treatment for 48 hours, an acute treatment with BDNF was applied for 10 min in
cultured DRG neurons. Phospho-ERK is shown by green fluorescence and TNFR1 is shown by red fluorescence. (B-D) Photomicrographs illustrate
the immunoreactivity of phospho-ERK (B) and TNFR1 (C) in DRG cultures of the control group (no TNF-a pre-treatment). (D) Merged image of (B)
and (C). (E-G) Photomicrographs illustrate the immunoreactivity of phospho-ERK (E) and TNFR1 (F) in DRG cultures of the TNF-a group. (G)
Merged image of (E) and (F). Inserts illustrate the phospho-ERK and TNFR1 signals that co-localized in a DRG neuron. Wide arrow, co-localized
phospho-ERK and TNFR1; narrow arrow, TNFR1; arrowhead, phospho-ERK. Scale bars, 50 μm.
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Page 14 of 22In the present study, we found that BDNF protein but
not mRNA was significantly enhanced in DRG during
inflammation. Previously, it has been reported that levels
of BDNF mRNA increase significantly in DRG 24 hours
after CFA-injection [29,34], while CFA-induced BDNF
protein is up-regulated in DRG (L5) for up to 4 days
[35]. Since we observed an increase in the amount of
BDNF protein in DRG 72 hours after CFA injection, it
is possible that transcriptional regulation occurs only
during an early phase while translational regulation lasts
longer. In further support of this concept, TNF-a was
previously found to enhance BDNF protein expression
at 24 hours, but to increase mRNA expression at 4
hours [36]. Consistent with this notion, we did detect an
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Figure 10 BDNF-induced phospho-ERK immunohistochemical signals in DRG cultures after TNF-a treatment. Phospho-ERK signals were
detected after a 5 nM TNF-a pre-treatment for 48 hours followed by 400 ng/ml BDNF for 0-40 min. Phospho-ERK and TNFR1 proteins were
detected by double immunofluorescent stain. Photomicrographs illustrate the protein signals of individual phospho-ERK and TNFR1 or merged
phospho-ERK/TNFR1 in control (no TNF-a pre-treatment) (A) and TNF-a groups (B). Scale bars, 50 μm.
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Page 15 of 22up-regulation of BDNF mRNA 6 hours after TNF-a
treatment in DRG cultures. The differential regulation
of transcription and translation might also explain the
results obtained in CGRP mRNA and protein, both in
vivo and in vitro.
Our results reveal a statistically significant increase in
protein levels of trkB, BDNF and CGRP as well as
mRNA of trkB and TRPV1, mainly in L3, but CGRP
protein in L4 and trkB and CGRP proteins in L5 DRG
after CFA treatment. On the other hand, TNF-a treat-
ment led to increased protein levels of trkB, BDNF and
CGRP predominantly in L4, with relatively minor effects
in L3 and L5 DRGs. This segregated effect was unex-
pected because rat hindpaw are innervated by primary
afferents from L3, L4 and L5 DRGs. A previous report
regarding the nociceptive dermatomes in Wistar rat
hindpaw demonstrated that the L3 dermatome is con-
tained in the inner part of the paw; the L4 dermatome
is contained in the middle part of the paw and the L5
dermatome is contained in the outside part of the paw
[37]. Although swelling was visually observed in the
entire hindpaw, a differential response was found among
the individual segments of lumbar DRG. In support of
the notion that segments of the lumbar DRG may
respond differently to injury, it has been previously
reported, for an animal model of neuropathic pain via
L5 spinal nerve ligation, that expression of BDNF and
TRPV1 are up-regulated in uninjured L4 DRG [38].
Similarly, expression of TNFR1 and TNFR2 are
increased in injured L5 and uninjured L4 DRG after L5
spinal nerve ligation [39,40]. In addition, our results
showing differential effects in L3 and L4 in response to
CFA and TNF-a might be due to drug formulation, i.e.
chyle form of CFA vs. liquor form of TNF-a. A detailed
explanation of the cause of uneven sensitivity between
L3, L4 and L5 DRGs after CFA or TNF-a hindpaw
treatment requires further investigation.
Pro-inflammatory cytokines play an important role in
the process of inflammatory pain and their release results
in pain sensitization [2,3]. TNF-a is a potent cytokine,
and intraplantar injection of TNF-a in rats has been pre-
viously shown to produce mechanical hyperalgesia while
TNF-neutralizing antibodies reverse TNF-a-induced
nociception [1,8]. Furthermore, TNF-a increases expres-
sion of TRPV1 in DRG via TNFR1 receptor with a
requirement for ERK signaling [11]. Interestingly, anti-
TNF-a treatment in patients with rheumatoid arthritis
results in decreased plasma BDNF [41]. TNF-a can also
enhance expression of BDNF protein in trigeminal gang-
lion neuronal cultures [36]. Hence, it is plausible that a
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Figure 11 BDNF-induced phospho-ERK1/2 in DRG cultures after TNF-a treatment. DRG cultures were treated with 5 nM TNF-a for 48
hours prior to 400 ng/ml BDNF. Protein signals were detected by western immunoblot up to 40 min after BDNF treatment. (A, B) Gel pictures
illustrating the phospho-ERK1/2 and b-actin signals in control (no drug treatment) and TNF-a-treated groups, respectively. (C, D) Quantitative
measurements of phospho-ERK1 and phospho-ERK2 signals in control and TNF-a-treated groups, respectively. The results are presented as ratios
relative to b-actin. The data are expressed as mean ± SEM and were analyzed using one-way ANOVA followed by Tukey test, *p < 0.05, **p <
0.01, ***p < 0.001; compared to time 0. The comparison between basal TNF-a and control groups were analyzed using an un-paired Student’s
t-test;
##p < 0.01,
###p < 0.001, (N = 6 per group).
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Figure 12 Apoptosis analyses after acute BDNF treatment after TNF-a treatment. DRG cultures were pre-treated with 5 nM TNF-a for 48
hours followed by 400 ng/ml BDNF for 10 or 40 min. Cells were immediately fixed and apoptotic cells were detected by TUNEL reaction kit. (A)
Control group; (B) TNF-a-pretreated group. DNase I-treated cells served as a positive control, while reaction enzyme removal served as a
negative control. TUNEL staining was detected with a fluorescent green dye and cells were counterstained with DAPI. Insert illustrates an
apoptotic cell from the positive control. Scale bars, 50 μm.
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Figure 13 Basal and drug-evoked CGRP and substance P release in DRG cultures.A f t e ra5n MT N F - a treatment for 48 hours, 400 ng/ml
BDNF was added for 30 or 60 min. The supernatants were collected and subjected to CGRP and substance P EIA analysis. Data are expressed as
mean ± SEM, presented as percentage of control. Data from BDNF treatment were analyzed using one-way AVOVA followed by Tukey test, *p <
0.05, ***p < 0.001; compared corresponding basal groups. The comparison between TNF-a and control groups was analyzed using an un-paired
Student’s t-test,
##p < 0.01,
###p < 0.001 (N = 5~7 per group).
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Figure 14 Retrograde transport of TNF-a and TNFR1 expression in DRG. (A) After CFA injection (48 hours), TNF-a (labeled with Alexa Fluor
488) was injected into rat hindpaw with free Alexa Fluor 488 as a control. Twenty-four hours later, saphenous nerve was isolated and
fluorescent signals were detected using a fluorescence microscope. Photomicrographs illustrate three different segments: Distal, middle and
proximal. Scale bars, 50 μm. Inserts illustrate magnified axon fibers labeled with Alexa Fluor 488 with scale bars of 20 μm. (B-C)
Photomicrographs illustrate TNFR1 immunoreactivity, detected by immunefluorescent stain. (B) Seventy-two hours after CFA injection, L3-L5
DRGs were collected. (C) TNF-a treatment for 48 hours in DRG cultures. Scale bars, 50 μm. Bar graphs represent quantitative measurements of
TNFR1 fluorescent intensity. The data are presented as fluorescent intensity of immunopositive neurons, expressed as mean ± SEM and were
analyzed using an un-paired Student’s t-test. **p < 0.01 (N = 3 per group); compared to control.
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system in DRG mediates inflammation-induced hyperal-
gesia. In this study, we first demonstrated that levels of
TNF-a were raised significantly in the inflamed tissues,
as compared to uninjured hindpaw, thereby confirming a
role for TNF-a during inflammation. Further, we proved
that inflammatory hyperalgesia could be induced by
direct TNF-a injection into hindpaw. The finding that
TNF-a in DRG is undetectable after animals develop
hyperalgesia is surprising,b u tm a yb ee x p l a i n e db yt h e
following considerations. First, mono-arthritis developed
under the current experimental conditions, which
amounts to an early inflammatory stage confined mainly
to the affected tissues. The resulting inability to detect
TNF-a in serum is similar to the findings of a previous
report [42], and seems to support this argument. Second,
TNF-a produced locally in injured tissues would act on
TNF-a receptors found on free nerve endings and
undergo retrograde transport to DRG. This phenomenon
was recently demonstrated in a rat model of carragee-
nan-induced inflammation [27] as well as a rat model of
peripheral nerve injury [28]. In the present study, we vali-
dated the ability of TNF-a to undergo retrograde trans-
port along the saphenous nerve in a CFA-induced
inflammatory rat model. The axonal transport pattern
and speed are comparable with previous observations
using a carrageenan-induced pain model [27]. Hence,
rather than massive TNF-a accumulation in DRG that
would be expected to occur at a late stage of inflamma-
tion (progressive poly-arthritis), we speculate that in the
current model, intracellular TNF-a carried by the TNF-a
receptor is the main participant in the DRG, although we
could not exclude the possibility that TNFR1 expression
resulted from inflammation while independent from
translocation.
Similar to the CFA-induced inflammatory condition,
we found that TNF-a injection into hindpaw and appli-
cation to DRG cultures produced a clear enhancement
o ft r k Ba n dB D N Fe x p r e s s i o ni nD R G .I na d d i t i o n ,w e
observed a release of BDNF from DRG cultures after
TNF-a treatment. Other than targeting the post-synap-
tic trkB receptor in the dorsal horn, we speculate that
enhanced BDNF would also have chance to activate
local trkB receptors in DRG, leading to trkB dimeriza-
tion and auto-phosphorylation, which would ultimately
trigger pre-synaptic signaling pathways [43]. In support
of this hypothesis, our results demonstrate that activa-
tion of trkB receptors by BDNF enhances phospho-
ERK1/2 signal in TNF-a-pretreated animals, suggesting
that a possible intra-DRG BDNF-trkB system could be
functionally self-activated under chronic TNF-a expo-
sure. However, we observed an inconsistent result for
basal phospho-ERK1/2 signal after TNF-a pretreatment
(i.e. an increase in IHC but a decrease in western blot).
Other than a difference possibly due to analytical meth-
ods, the impact of TNF-a on overall basal MAPK signal
requires further investigation. The dual observations
that both BDNF and BDNF-triggered phospho-ERK sig-
nals largely co-localize with TNFR1 suggest that TNFR1
might associate with in situ BDNF-trkB up-regulation.
In addition to the effect of TNF-a on BDNF-trkB, it is
well known that TNF-a can induce IL-6, IL-8 and gran-
ulocyte-macrophage colony-stimulating factor (GM-
CSF) secretion through activation of MEK1/2, p38
MAPK and NF-B pathways during inflammation
[44,45]. Since a notable inflammation was observed in
both CFA- and TNF-a-treated hindpaw, we could not
exclude the possibility that a combined action of these
chemical mediator(s) might work synergistically to up-
regulate the BDNF-trkB system in vivo.
NGF is an important mediator of inflammatory pain
[13]. After release from immune cells, NGF binds with
trkA to form an NGF/trkA complex which is then retro-
gradely transported to DRG to up-regulate expression of
genes, such as those for TRPV1, BDNF, CGRP and sub-
stance P [2,3] via ERK, PI3K, p38 MAPK or CaMKII sig-
naling [5,14,15,46]. TNF-a has also been shown to
enhance NGF expression in vivo [42], although NGF does
not appear to be involved in TNF-a-mediated BDNF up-
regulation in trigeminal ganglia cultures [36]. Our observa-
tion that TNF-a and NGF can both induce BDNF expres-
sion in DRG cultures suggests a functional synergism
between these two chemical mediators. However, the
increase of BDNF by TNF-a may be derived from astro-
cytes within the cultures [47]. Although Ara-C was applied
in our DRG culture system, we cannot totally exclude the
possibility that enhanced TNF-a/NGF-induced BDNF
could be partially due to contaminating satellite cells.
Our results show that BDNF treatment increases
mRNA expression for trkB receptor in DRG cultures.
BDNF is reported to co-express with trkA (20%) and
trkB (10%) receptors in DRG [18,21]. In addition, BDNF
is thought to act as an autocrine or paracrine signal regu-
lating trkB in sensory neurons [16,48]. Low doses of
BDNF up-regulate trkB receptors while high doses down-
regulate trkB receptors [49]. Our in vitro results demon-
strate that an increase in trkB receptors is triggered by
either BDNF or TNF-a. This effect may eventually form
a sensitization loop to increase pain transmission at the
level of the DRG.
The finding that basal CGRP release is enhanced in
DRG after chronic TNF-a treatment supports a previous
study which showed that acute TNF-a treatment increases
CGRP release in rat trigeminal ganglia [50]. In addition,
these results also correspond with our in vivo and in vitro
observations that total CGRP protein increases after CFA-
induced inflammation [36,50]. Similarly, we found that
chronic TNF-a treatment results in enhanced basal
Lin et al. Journal of Neuroinflammation 2011, 8:126
http://www.jneuroinflammation.com/content/8/1/126
Page 19 of 22substance P release in DRG cultures. Acute BDNF stimu-
lation could induce an increase in substance P release 60
min after treatment, but had no effect after TNF-a pre-
treatment. The findings are consistent with previous
reports [23,31] that BDNF can stimulate CGRP and sub-
stance P release under basal conditions via trkB receptor
in spinal cord. TNF-a regulation of substance P release
has never been studied in DRG, though Ansal et al [51]
reported that substance P induces TNF-a mRNA expres-
sion and release in mast cells. In addition, substance P
enhances mechanical allodynia and heat hyperalgesia in
pre-protachykinin A
-/- mice through the actions of NGF
and TNF-a [52]. In this manuscript, we demonstrate that
TNF-a pre-treatment enhances the production and basal
release of CGRP and substance P, consequently facilitating
pain transmission. The lack of a trkB effect on CGRP/sub-
stance P release during inflammation suggests that a maxi-
mal effect is already achieved by TNF-a pre-treatment.
Conclusions
We hypothesize that during chronic inflammation, cyto-
k i n e ss u c ha sT N F - a are released locally and act on
TNF receptors in nociceptors. TNF-a then undergoes
retrograde transport to the DRG to enhance synthesis of
BDNF, trkB and CGRP. NGF may also be released from
immune cells around nociceptors and bind to trkA
receptor to further increase the expression of TRPV1,
BDNF and CGRP. The enhanced BDNF in DRG might
have chance to act as an autocrine and/or paracrine sig-
nal to activate pre-synaptic trkB receptors synergistically
with cellular events mediated by TNF-a (or by other
inflammatory mediators), and up-regulate synaptic excit-
ability in pain transmission (see Figure 15 for a working
model). The identification of the cellular mechanism(s)
underlying the DRG BDNF-trkB system in inflammatory
pain may provide novel therapeutic targets to combat
chronic pain.
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